Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Alivus Life Sciences Limited (NSE: ALIVUS), ISIN INE03Q201024 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
ALIVUS last traded at ₹1474.95 (-0.38%), with a 52-week range of ₹819.00 to ₹1574.00 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 74.85%, FIIs 5.93%, DIIs 7.03%, mutual funds 5.29%.
EquiSense Score (ECS): 81/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.